At present, according to the Chinese Medical Association statistics, the size of the medical device market in China accounted for 14% of the total pharmaceutical market size, there is still a large gap compared with the global average of 42%, there is a broad market space for development.http://www.shinehe.com/
High precision filter function and medical infusion device sales region and customer service technical support in the industry with higher requirements, the dealer sales mode for sale to the hospital, into the advanced industry enterprises expansion through long-term channels, develop a group with strong market development ability, management ability and professional service capabilities of high-quality dealers and quickly occupied the channel resources, after the exclusion of entrants to the competition, formed a strong channel barriers.
technology and talent
Due to the high precision medical filter and function infusion device is directly applied to the human body, the state put forward higher requirements on the technology and production process, from production to final assembly parts often need to form the final product after a long time of development and testing, to reach the relevant technical indexes and reliability requirements. In the process of clinical use, the quality requirements of clinical medical staff and patients are higher.
The medical device industry enterprises to establish a perfect marketing channel network requires a large amount of capital investment and a long period of time, the market after a long-term accumulation to form a certain scale of the marketing network, thus forming obvious barriers to marketing ability.
Medical devices in clinical use, medical institutions tend to single or several specific types of suppliers, so that medical personnel to master the operation method of this kind of medical equipment, improve work efficiency, reduce the operation risk, and strengthen the bargaining power, reduce procurement costs. Therefore, the medical device products will be more exclusive in the process of clinical use, which will lead to a "dead end" for similar products intended to enter medical institutions